Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now later-stage tilt small index

Left Ventricular Hypertrophy: later-stage trial registry

7 of 8 indexed Left Ventricular Hypertrophy trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 7 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Left Ventricular Hypertrophy: 8 US clinical trials tracked, 7 recruiting.

Left Ventricular Hypertrophy is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition left-ventricular-hypertrophy

OPEN 7 | RECR 88% | LATE 2 | EARLY 1 | RANK #2176 | SPON 2

Nearest open-share peer: Aortic Diseases (88% recruiting · 8 trials)

Left Ventricular Hypertr (th…88%Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Left Ventricular Hypertrophy

Left Ventricular Hypertrophy lists 7 open slots (88% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Left Ventricular Hypertrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Left Ventricular Hypertrophy is recruiting above its size-band peers.

    7 of 8 indexed trials (87.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Left Ventricular Hypertrophy research.

    Massachusetts General Hospital accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Left Ventricular Hypertrophy enrolment sits around 160 participants.

    Median target enrolment is 160 among the 8 trials that report a genuine target (sentinel values excluded). 2 of those (25%) plan for fewer than 100 participants.

  4. Left Ventricular Hypertrophy research is mostly interventional.

    6 interventional and 2 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Left Ventricular Hypertrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Losartan 50/100 mg placebo Drug
1 trials
Aliskiren placebo Drug
1 trials
Losartan 50/100 mg Drug
1 trials
Aliskiren 150/300 mg Drug
1 trials
Gadolinium DOTA Meglumine Drug
1 trials
Diffusion Tensor MRI (DTI) Device
1 trials
Potassium Drug
1 trials
Eplerenone Drug
1 trials

US sites by state

Facility locations filed on Left Ventricular Hypertrophy trials. A trial with sites in several states counts in each.

Massachusetts 4 trials
New Jersey 1 trials
North Carolina 1 trials
Louisiana 1 trials
Connecticut 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Left Ventricular Hypertrophy page

8 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Left Ventricular Hypertrophy condition card totals 8 registered trials; most-linked intervention Losartan 50/100 mg placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.